Is CL a Buy? What to Consider in 2026
Last updated June 2026
Short answer
There is no universal answer to whether CL is a buy; it depends on your thesis, time horizon, and what you already own. Below is the case for Colgate-Palmolive, the main risks to weigh, where the stock trades, and a framework to decide for yourself. This is informational, not a recommendation, and Walnut is not an investment adviser.
Colgate-Palmolive is a global consumer-staples company that makes everyday household and personal-care products. It is a worldwide leader in oral care, where its Colgate-branded toothpaste, toothbrushes, and mouthwash hold a leading global share, and it also sells personal care (soaps, body wash, deodorants under brands like Palmolive, Softsoap, Irish Spring, and Sanex), home care (dish and surface cleaners such as Palmolive and Ajax), and pet nutrition through its Hill's Pet Nutrition business (Science Diet and Prescription Diet). Colgate makes money by selling these branded, frequently repurchased products at scale across more than 200 countries and territories, with a particularly large presence in emerging markets. Its competitive advantages come from powerful brands, vast distribution, and pricing power on staple goods. Headquartered in New York City, Colgate is a defensive, dividend-paying company whose products people buy regardless of the economic cycle.
The case for Colgate-Palmolive
1. Oral-care leadership and emerging markets.
Colgate holds a leading global share in toothpaste and a strong position in toothbrushes and mouthwash, with deep penetration in emerging markets across Latin America, Africa, and Asia. Rising incomes and growing oral-care adoption in these regions provide a long, steady volume runway, and the brand's dominance supports consistent pricing power on a daily-use staple.
2. Hill's Pet Nutrition growth.
Hill's, Colgate's premium science-based pet food business, has been a standout growth engine. Pet humanization and the shift toward premium, veterinary-recommended nutrition support durable demand. Hill's diversifies Colgate beyond personal and home care into a higher-growth, higher-margin category with strong customer loyalty.
3. Pricing power and margin recovery.
As a maker of low-ticket staples with strong brands, Colgate can raise prices to offset input-cost inflation with limited volume loss. Productivity programs, premiumization, and easing commodity costs support gross-margin recovery and steady earnings, while advertising investment protects market share against private label and challengers.
4. Defensive cash returns.
Colgate generates reliable free cash flow from frequently repurchased products and is a Dividend King, having raised its dividend for decades. It returns cash through a steady, growing dividend and buybacks, making it a classic defensive holding that tends to hold up better than the market during economic stress.
The risks to weigh
Colgate's growth is structurally slow: it competes in mature, saturated staples categories where volume gains are hard to come by and much of recent revenue growth has come from price increases that may not persist. It faces intense competition from Procter and Gamble, Unilever, and private-label brands, plus pressure from retailers. Heavy emerging-market exposure brings currency volatility that can erode reported results. Input-cost inflation, the rise of private label during cost-of-living squeezes, and the challenge of sustaining pricing without losing volume all weigh on the outlook. The defensive premium valuation can also compress when investors rotate toward higher-growth or cyclical names.
Valuation context (as of early 2026)
- Revenue (TTM): ~$20 billion
- Operating margin: ~20-21%
- Net income (TTM): ~$2.7 billion
- Dividend yield: ~2-2.5% (Dividend King)
- P/E (TTM): ~22-26x, a defensive premium
- Free cash flow: strong and consistent
- Segments: Oral, Personal and Home Care; Hill's Pet Nutrition
Colgate trades at a premium consumer-staples multiple that reflects its defensive, recession-resistant cash flows, leading oral-care brands, the growth of Hill's, and a multi-decade dividend-raising record. The valuation premium is the market paying for stability and pricing power, balanced against the reality of slow underlying volume growth in mature categories.
How to decide for yourself
Rather than asking whether CL is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold CL indirectly through an index or sector ETF before adding more.
For the full picture, see the CL stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about CL against your real portfolio and see your actual exposure before deciding.
Build a basket around CL with Walnut
Use Colgate-Palmolive as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is CL a good stock to buy right now?
+
There is no universal answer. Whether Colgate-Palmolive fits depends on your thesis, time horizon, risk tolerance, and what you already own. This page lays out the case for, the main risks, and where the stock trades, so you can decide for yourself. Walnut is not an investment adviser and this is not a recommendation.
What does Colgate-Palmolive do?
+
Defensive consumer-staples leader in oral care plus Hill's pet nutrition, with a multi-decade Dividend King record.
What are the main risks of CL?
+
Colgate's growth is structurally slow: it competes in mature, saturated staples categories where volume gains are hard to come by and much of recent revenue growth has come from price increases that may not persist. It faces intense competition from Procter and Gamble, Unilever, and private-label brands, plus pressure from retailers. Heavy emerging-market exposure brings currency volatility that can erode reported results. Input-cost inflation, the rise of private label during cost-of-living squeezes, and the challenge of sustaining pricing without losing volume all weigh on the outlook. The defensive premium valuation can also compress when investors rotate toward higher-growth or cyclical names.
What is CL's ticker symbol?
+
CL, listed on the New York Stock Exchange. The company is Colgate-Palmolive Company, headquartered in New York City. It trades during US market hours and is available at every major US brokerage.
What does Colgate-Palmolive do?
+
Colgate-Palmolive makes everyday consumer products: oral care (Colgate toothpaste and toothbrushes), personal care (Palmolive, Softsoap, Irish Spring), home care (dish and surface cleaners), and pet nutrition through Hill's. It sells these branded staples in more than 200 countries.
Who are Colgate's main competitors?
+
In oral and personal care, Procter and Gamble, Unilever, Church and Dwight, and Haleon. In home care, Reckitt and Clorox. In pet nutrition, Mars and Nestle Purina compete with Hill's.
Is Colgate a defensive stock?
+
Yes. Colgate sells frequently repurchased staples that people buy regardless of the economy, giving it stable demand, reliable cash flow, and a steady dividend. It is a classic defensive holding that often outperforms during recessions and market stress.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell CL; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.